| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ENO2; Gamma-enolase; 2-phospho-D-glycerate hydro-lyase; Enolase 2; Neural enolase; Neuron-specific enolase; NSE |
| Entrez GeneID | 2026 |
| WB Predicted band size | Calculated MW: 47 kDa; Observed MW: 47 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Recombinant protein of human NSE |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于NSE(神经元特异性烯醇化酶)抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Neuron-specific enolase as a biomarker: biochemical and clinical aspects*
**作者**: Isgrò, M. A., Bottoni, P., & Scatena, R.
**摘要**: 该综述探讨了NSE作为神经内分泌肿瘤(如小细胞肺癌)和神经系统疾病(如脑损伤)生物标志物的临床应用。文中重点讨论了NSE抗体的检测方法(如ELISA、免疫组化)及其在疾病诊断和预后评估中的价值。
---
2. **文献名称**: *Serum neuron-specific enolase in human traumatic brain injury*
**作者**: Böhmer, A. E., et al.
**摘要**: 研究通过检测创伤性脑损伤患者血清中的NSE水平，发现其浓度与损伤严重程度及神经功能预后显著相关。NSE抗体的定量分析被证明是评估继发性脑损伤和制定治疗策略的重要工具。
---
3. **文献名称**: *Development of a novel monoclonal antibody against human neuron-specific enolase*
**作者**: Kumar, S., et al.
**摘要**: 该研究报道了一种新型高特异性NSE单克隆抗体的开发，验证了其在免疫印迹和免疫组织化学中的应用效果。此抗体对神经源性肿瘤的精准检测具有潜在临床价值。
---
4. **文献名称**: *NSE in cerebrospinal fluid: a marker for neuronal damage in neurodegenerative diseases*
**作者**: Blennow, K., et al.
**摘要**: 通过分析阿尔茨海默病和血管性痴呆患者的脑脊液NSE水平，发现其浓度升高与神经元损伤程度相关。研究强调了NSE抗体检测在神经退行性疾病早期诊断中的意义。
---
以上文献覆盖了NSE抗体在肿瘤诊断、脑损伤评估、抗体开发及神经退行性疾病研究中的应用场景。
Neuron-specific enolase (NSE) antibodies are immunological tools targeting the gamma (γ) isoform of the enolase enzyme, primarily expressed in neurons, neuroendocrine cells, and certain tumors. NSE, encoded by the ENO2 gene, is a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate. Its restricted expression in mature neurons and peripheral neuroendocrine tissues makes it a valuable biomarker in research and diagnostics.
NSE antibodies are widely used in immunohistochemistry, ELISA, and Western blotting to identify neuronal differentiation, map neural networks, or detect neuroendocrine tumors (e.g., small cell lung cancer, neuroblastoma). Elevated NSE levels in blood or cerebrospinal fluid correlate with neuronal damage, such as in traumatic brain injury, stroke, or neurodegenerative diseases. However, cross-reactivity with non-neuronal enolase isoforms (e.g., in erythrocytes) may cause false positives, necessitating careful validation.
First isolated in the 1970s, NSE gained clinical relevance as a tumor marker in the 1980s. Modern monoclonal NSE antibodies offer improved specificity, aiding in differential diagnosis and therapeutic monitoring. Despite advances, challenges remain, including variable sensitivity in early-stage diseases and interference from hemolysis. Ongoing research explores its role in cancer metastasis and neurological disorders, underscoring its dual utility in both basic neuroscience and clinical pathology.
×
